跳转至内容
Merck
CN
  • Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis.

Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis.

Joint, bone, spine : revue du rhumatisme (2014-01-07)
Glen S Hazlewood, Claudia Metzler, George A Tomlinson, Wolfgang L Gross, Brian M Feldman, Loic Guillevin, Christian Pagnoux
摘要

To determine the comparative efficacy of non-biologic treatments for remission maintenance in ANCA-associated vasculitis. We identified all randomized trials comparing leflunomide, azathioprine, methotrexate or mycophenolate mofetil in adult patients with granulomatosis with polyangiitis or microscopic polyangiitis. Relapse-free survival was compared through hazard ratios (HR) using a Bayesian fixed-effects network meta-analysis. Multiple sensitivity analyses were performed to explore biases identified in one trial using original trial data. Three trials were available (leflunomide-methotrexate, methotrexate- azathioprine, azathioprine-mycophenolate). Mycophenolate was inferior to all treatments, although the 95% credible interval (CrI) of the HR relative to methotrexate crossed 1. Leflunomide was superior to azathioprine (HR 0.43 [95% CrI: 0.14-1.3]) and methotrexate (HR 0.47 [95% CrI: 0.18-1.2]), although the 95% CrI also crossed 1. There was a 90% probability that leflunomide was the best treatment. After down weighting the effect of leflunomide vs. methotrexate for early trial termination and slow MTX dose escalation, there remained a 55% probability leflunomide was best. Based on indirect evidence, leflunomide is effective in maintaining remission in granulomatosis with polyangiitis or microscopic polyangiitis relative to other non-biologic treatments. Further randomized trials of leflunomide are needed for confirmation.

材料
产品编号
品牌
产品描述

USP
霉酚酸酯, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
硫唑嘌呤, ≥98%
Sigma-Aldrich
来氟米特, Immunosuppressant
Supelco
霉酚酸标准液 CRM 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
来氟米特, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
硫唑嘌呤, Pharmaceutical Secondary Standard; Certified Reference Material
硫唑嘌呤, European Pharmacopoeia (EP) Reference Standard
USP
来氟米特, United States Pharmacopeia (USP) Reference Standard
霉酚酸酯, European Pharmacopoeia (EP) Reference Standard
吗替麦考酚酯, European Pharmacopoeia (EP) Reference Standard
来氟米特, European Pharmacopoeia (EP) Reference Standard
来氟米特, European Pharmacopoeia (EP) Reference Standard